Radius Health reports Q2 EPS ($2.22), may not compare to consensus (89c) The net loss per share calculation for the three months ended June 30 includes the weighted average impact of Radius' convertible preferred stock converting into common stock upon the completion of its initial public offering in June. The decrease in net loss for the 2014 period was primarily due to a decrease in research and development expenses.
Radius Health price target raised to $52 from $26 at Cantor Cantor doubled its price target on Radius Health to $52 from $26 after the company reported Phase III trial data the firm views as having significantly de-risked its development of abaloparatide-SC for the treatment of severe post-menopausal osteoporosis. Cantor maintains its Buy rating on Radius shares.
Radius Health ACTIVE Phase 3 clinical trial meets primary endpoint Radius Health announced positive top-line 18-month fracture results from the company's Phase 3 clinical trial, known as ACTIVE, evaluating the investigational drug abaloparatide-SC for potential use in the reduction of fractures in postmenopausal osteoporosis. On the primary endpoint, the investigational drug abaloparatide-SC achieved a statistically significant 83% reduction of incident vertebral fractures as compared to the placebo-treated group. The ACTIVE trial included an open-label teriparatide injection treatment group that showed a statistically significant 78% reduction of incident vertebral fractures as compared to the placebo-treated group. On the secondary endpoints as compared to placebo, abaloparatide-SC achieved a statistically significant fracture-rate reduction of 43% in the adjudicated non-vertebral fracture subset of patients; a statistically significant reduction of 41% in the adjudicated clinical fracture group, which includes both vertebral and non-vertebral fractures; and a statistically significant difference in the time to first incident non-vertebral fracture in both the adjudicated non-vertebral fracture and the clinical fracture subset of patients.